SRR12475159
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- MYC_TARGETS_V1+0.550
- MYC_TARGETS_V2+0.510
- G2M_CHECKPOINT+0.490
- INTERFERON_ALPHA_RESPONSE+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.410
- TNFA_SIGNALING_VIA_NFKB+0.390
- MTORC1_SIGNALING+0.380
- DNA_REPAIR+0.290
- INTERFERON_GAMMA_RESPONSE+0.240
Top 10 suppressed
- MYOGENESIS-0.350
- APICAL_JUNCTION-0.280
- HEDGEHOG_SIGNALING-0.250
- HEME_METABOLISM-0.220
- KRAS_SIGNALING_DN-0.190
- ADIPOGENESIS-0.170
- PEROXISOME-0.160
- APICAL_SURFACE-0.150
- FATTY_ACID_METABOLISM-0.150
- ANGIOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7cec44f2-b56b-49fc-b2cc-d0691afde776 | — | — | 0.868 |
| 2 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.836 |
| 3 | TCGA-D8-A1XK-01A-21R-A14M-07 | — | E | 0.835 |
| 4 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.831 |
| 5 | TCGA-CV-5977-01A-11R-1686-07 | — | — | 0.831 |
| 6 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.829 |
| 7 | SRR6013496 | — | cohortA4 | 0.826 |
| 8 | SRR934912 | — | — | 0.818 |
| 9 | SRR934964 | — | — | 0.815 |
| 10 | 78699d1d-aa39-473a-b3ea-24164d3a443c | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |